AGLE - Aeglea BioTherapeutics Inc (Healthcare: Biotechnology) Projected Earnings Date: 2024-06-07    (Delayed quote data   )
Last
 		 Change
 ⇓ 0.00   (%)		 Volume
  0
Open
 		 High
 		 Low
 
8EMA (Daily)
 0.00		 40EMA (Daily)
 		 50EMA (Daily)
 		 STO (Daily)
 		 MACD Hist (Daily)
 
8EMA (Weekly)
 10.965		 40EMA (Weekly)
 5.93		 50EMA (Weekly)
 5.22		 STO (Weekly)
 64.595		 MACD Hist (Weekly)
 -0.045
Company Profile
Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an early clinical development stage.
optionchance optionchance
⇒ Home | Chart and Research | Education | About Us  

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Questions or Comments: support@optionchance.com
Copyright © 2025 OptionChance.com